What we know of Leronlimab is a 24% reduction in c

What we know of Leronlimab is a 24% reduction in critical, with no SAEs, and a 6 day reduction in hospital stay. As Doc 500 has said, this would be a perfect use of the EUA. If for some reason, greater numbers of critical patients produce a much different result, the EUA could be withdrawn. FDA does not want to give full approval because explaining that decision if results change would diminish FDA status. (I very much doubt that our results with more patients would be less efficacious but it certainly is what the EUA is for). So all of you longs, with your left hand keep commenting on Investors Hangout but with your right hand, write to every social media forum you can find and make sure the FDA knows we are watching. We know the Leronlimab efficacy on critical patients and we know that EUA is the right decision. Maybe Canada, Brazil or Philippines will act more promptly because they have a different paradigm and do not fear economic sanctions